BRIEF COMMUNICATION

Small intestinal bacterial overgrowth prevalence in celiac disease patients is similar in healthy subjects and lower in irritable bowel syndrome patients

J.S. Lasa*, I. Zubiaurre, I. Fanjul, P. Olivera, L. Soifer

Sección de Gastroenterología, Departamento de Medicina Interna, CEMIC, Buenos Aires, Argentina

Received 28 January 2015; accepted 30 April 2015
Available online 6 July 2015

KEYWORDS
Celiac disease;
Small intestinal bacterial overgrowth;
Irritable bowel syndrome

Abstract

Background: Untreated celiac disease has traditionally been linked to a greater risk for small intestinal bacterial overgrowth, but the existing evidence is inconclusive.
Aims: To compare the prevalence of small intestinal bacterial overgrowth in subjects with celiac disease compared with control subjects and patients with irritable bowel syndrome.
Material and methods: The study included 15 untreated celiac disease patients, 15 subjects with irritable bowel syndrome, and 15 healthy controls. All enrolled patients underwent a lactulose breath test measuring hydrogen and methane. Small intestinal bacterial overgrowth was defined according to previously published criteria.
Results: No differences were found in relation to age or sex. The prevalence of small intestinal bacterial overgrowth was similar between the celiac disease patients and the controls (20 vs. 13.33%, P = NS), whereas it was higher in patients with irritable bowel syndrome (66.66%, P < 05).
Conclusion: There was no difference in the prevalence of small intestinal bacterial overgrowth between the untreated celiac disease patients and healthy controls.

© 2015 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article as: Lasa JS, Zubiaurre I, Fanjul I, Olivera P, Soifer L. La prevalencia de sobrecrecimiento bacteriano en celiacos es similar a la de sujetos sanos y menor que en pacientes con síndrome de intestino irritable. Revista de Gastroenterología de México. 2015;80:171-174.

* Corresponding author. Austria 1958 (1425) (5411)4823-4642.
E-mail address: drjuanslasa@gmail.com (J.S. Lasa).
La prevalencia de sobrecrecimiento bacteriano en celiacos es similar a la de sujetos sanos y menor que en pacientes con síndrome de intestino irritable

Resumen
Introduction: Clásicamente, se ha vinculado a la enfermedad celiaca no tratada con un mayor riesgo de sobrecrecimiento bacteriano. Sin embargo, la evidencia existente no es concluyente. Objetivo: Comparar la prevalencia de sobrecrecimiento bacteriano en sujetos celiacos con respecto a sujetos controles y a pacientes con síndrome de intestino irritable.
Material y método: Fueron inscritos 15 pacientes celiacos no tratados, 15 sujetos con síndrome de intestino irritable y 15 sujetos controles sanos. Los pacientes inscritos realizaron un test de hidrógeno/metano en aire inspirado con lactulosa. Se definió al sobrecrecimiento bacteriano según criterios previamente publicados.
Resultados: No se encontraron diferencias en cuanto a edad y sexo. La prevalencia de sobrecrecimiento bacteriano fue similar entre celiacos y controles (20 vs. 13.33%, p = NS), mientras que fue mayor en pacientes con síndrome de intestino irritable (66.66%, p < 0.05).
Conclusión: Los celiacos no tratados presentan una prevalencia de sobrecrecimiento bacteriano no diferente a los sujetos sanos.

© 2015 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
Celiac disease is an immunologic disorder in which an inflammatory alteration is produced due to exposure to gluten, with varying degrees of villous atrophy and nutrient malabsorption. Current treatment consists of a gluten-free diet.

Untreated and/or refractory celiac disease has traditionally been linked to a greater risk for developing small intestinal bacterial overgrowth, but conclusive evidence with respect to this is lacking. Small intestinal bacterial overgrowth diagnosis is difficult. A noninvasive alternative is the hydrogen/methane breath test. Its usefulness for this purpose is controversial because of the influence of bowel transit time on the results. Nevertheless, it continues to be a widely used tool in clinical practice.

The evidence with respect to the prevalence of small intestinal bacterial overgrowth measured by breath test in celiac disease subjects is scarce and contrasting. Therefore our aim was to compare the results of said test in celiac disease subjects with those of healthy controls and patients with irritable bowel syndrome (IBS) in whom such alteration is frequently observed.

Methods
Patient selection
Patients above the age of 18 years that were seen at the Gastroenterology Section of our institution within the time frame of January 2013 and December 2014 were evaluated. On the one hand, subjects were enrolled that had a recent diagnosis of celiac disease and that had not yet begun treatment with a gluten-free diet. Celiac disease patients were defined as those patients with positive IgA or IgG anti-tissue transglutaminase and/or anti-endomysial antibodies, together with a duodenal biopsy showing signs of villous atrophy (Marsh III).

On the other hand, subjects were enrolled that had IBS diagnosis without constipation and that were negative for celiac disease antibodies. IBS was defined in accordance with the Rome III criteria. And finally, healthy subjects seen at our institution for preventive clinical control were invited to participate if they did not present with digestive symptoms and were negative for celiac disease antibodies. The subjects were enrolled in a 1:1:1 ratio.

Those subjects suspected of concomitant digestive disease, that were pregnant, and patients that had taken antibiotics or probiotics within the last 30 days or prokinetics in the last 2 weeks, were excluded from the study.

Breath test
Once the written statements of informed consent were signed, the enrolled subjects were given a hydrogen/methane breath test utilizing lactulose as a substrate. The celiac disease subjects took the test before beginning the gluten-free diet. The tests were performed using the previously described technique: after the subjects fasted for 12 h and were on a low fermentable carbohydrate diet, they provided breath samples before (baseline sample) and after ingesting 10 ml of lactulose every 20 min for 180 min. The samples were analyzed with a chromatograph (BreathTracker® SC. QuinTron Instruments Company; Milwaukee, WI, USA) to determine the excreted hydrogen and methane concentrations, which were measured in particles per million (ppm). Curves were drawn illustrating the excreted gas concentrations in relation to time.

The presence of anomalous hydrogen and/or methane excretion considered consistent with small intestinal bacterial overgrowth was evaluated for each case. Any of the
following findings were regarded as abnormal: a) hydrogen excretion greater than 20 ppm before 90 min or an initial peak of 12 ppm before 90 min followed by a decrease of at least 5 ppm and a later increase (double hydrogen peak), and b) an increase in methane excretion greater than 3 ppm at any time during the test.

In addition, the presence of an elevated baseline value of hydrogen and/or methane (value greater than 3 ppm of methane and 12 ppm of hydrogen) was registered.

### Statistical analysis

Statistical analysis was carried out using the Stata® version 11.1 statistics program (Statacorp, College Station; Texas, USA). Numerical values were described as means with their standard deviations. Categorical variables were described as percentages. The ANOVA test was utilized for the numerical variable comparison and the Fisher test for comparing the categorical variables. Odds ratios (OR) were calculated with their corresponding 95% confidence intervals (95% CI). Statistical significance was set at a value of p less than 0.05.

### Results

A total of 15 recently diagnosed celiac disease patients, 15 patients with IBS, and 15 healthy controls were enrolled in the study. Table 1 shows the comparison of the demographic data, as well as the prevalence of small intestinal bacterial overgrowth measured by breath test by group.

There was significant difference in small intestinal bacterial overgrowth prevalence in IBS subjects with respect to the other 2 groups (66.66 vs. 20% in celiac disease patients and 13.33% in the controls). This difference presenting in the IBS patients was significant when compared with both the celiac disease group (OR 8 [1.52-42.01], p = 0.02) and the control group (OR 13 [2.07-81.48], p = 0.007). No differences were found between the celiac disease patients and the controls (OR 1.62 [0.23-11.46], p = NS). Even though the difference was not statistically significant, the celiac disease patients presented with a greater frequency of elevated baseline values compared with the other groups.

The patients that presented with a positive test for small intestinal bacterial overgrowth with compatible digestive symptoms were treated with 1,200 mg/day of rifaximin for 2 weeks. Two weeks after having finished treatment, 77% of the patients had complete symptom resolution. No significant differences were found in relation to the antibiotic response between the evaluated groups.

### Discussion

In accordance with our results, there was no difference in small intestinal bacterial overgrowth prevalence measured through breath test between untreated celiac disease patients and healthy controls, but there was increased prevalence in the IBS subjects.

There is evidence as to a relation between altered breath test results in an IBS context and small intestinal bacterial overgrowth prevalence measured by this method in more than 80% of the cases. In a celiac disease context, there is far less evidence.

In this sense, Corazza et al. have observed an increase in the baseline value of hydrogen in untreated celiac disease subjects; this alteration was corrected with a gluten-free diet. On the other hand, Chang et al. found no significant differences in hydrogen excretion between celiac disease patients and controls. Our experience with untreated active celiac disease patients was that hydrogen values were not different, compared with those of the controls, and they were significantly lower when compared with the IBS subjects. Celiac disease patients present with intestinal motility alterations that can predispose to small intestinal bacterial overgrowth; nevertheless, prevalence is variable. Most likely small intestinal bacterial overgrowth prevalence is greater in celiac disease patients with digestive symptoms related to gases. Therefore, it is to be expected that in an unselected celiac disease patient population, prevalence would be similar to that of the general population, as was shown in our study. The addition of excreted methane values provides a more complete perspective to previous studies that suggested these findings, only measuring hydrogen in the breath test.

Although the value of the lactulose breath test for small intestinal bacterial overgrowth diagnosis is debatable, it is undeniable that the difference in hydrogen and methane excretion reflects a difference in the fermentative capacity of non-absorbable substrates on the part of the gut microbiota, regardless of whether or not this results in actual small intestinal bacterial overgrowth. Thus, our experience was valuable in that we found a difference between patients with celiac disease and healthy controls in relation to patients with IBS. The relatively small sample size of our patient population should be underlined as a limitation of our study, as well as the fact that the patients did not undergo a duodenal aspirate culture. Even though it is regarded as the criterion standard diagnostic test, it can be difficult to reproduce.
In conclusion, the patients with untreated celiac disease presented with hydrogen and methane excretion profiles consistent with small intestinal bacterial overgrowth that were similar to those of subjects with no digestive disorders, but significantly different from those of patients with IBS.

Financial disclosure

No financial support was received in relation to this study/article.

Conflict of interest

The authors declare that there is no conflict of interest.

References